Inactive Instrument

Checkmate Pharmaceuticals, Inc.

Equities

CMPI

US1628181083

Biotechnology & Medical Research

Checkmate Pharmaceuticals, Inc. Announces the Retirement of Karen Brennan Retired from Her Position as Chief Operations Officer

October 05, 2020 at 08:03 am EDT

Effective September 30, 2020, Karen Brennan retired from her position as Chief Operations Officer of Checkmate Pharmaceuticals, Inc. Ms. Brennan’s retirement does not involve any disagreement on any matter relating to the Company’s operations, policies or practices. The Company’s executive officers will assume her responsibilities.

Latest news about Checkmate Pharmaceuticals, Inc.

Regeneron Completes Checkmate Pharmaceuticals Deal, Triggers $5 Million Milestone Payment to Kuros Biosciences	22-06-02	MT
Kuros To Receive $5 Million Milestone Payment from Regeneron's Acquisition Of Checkmate	22-06-02	MT
Checkmate Pharmaceuticals, Inc. Appoints Robert E. Landry as Chief Financial Officer	22-05-31	CI
Checkmate Pharmaceuticals, Inc. Announces Board Changes	22-05-31	CI
Checkmate Pharmaceuticals, Inc.(NasdaqGM:CMPI) dropped from NASDAQ Composite Index	22-05-31	CI
Checkmate Pharmaceuticals, Inc.(NasdaqGM:CMPI) dropped from S&P TMI Index	22-05-31	CI
Regeneron Pharmaceuticals, Inc. completed the acquisition of Checkmate Pharmaceuticals, Inc. from Decheng Capital China Life Sciences USD Fund III, L.P., a fund managed by Decheng Capital LLC, Arthur Krieg and others.	22-05-26	CI
University of Iowa Holden Comprehensive Cancer Center Presents Preliminary Data from Clinical Trial of Vidutolimod at the 2022 American Society of Clinical Oncology Annual Meeting	22-05-26	CI
Checkmate Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-12	CI
Kuros Biosciences' Q1 Medical Devices Sales Surge 102% Following US FDA Approval For MagnetOs	22-04-27	MT
BTIG Downgrades Checkmate Pharmaceuticals to Neutral From Buy	22-04-20	MT
Sector Update: Health Care Stocks Carried Higher in Rising Tuesday Markets	22-04-19	MT
Sector Update: Health Care Stocks Carried Higher in Rising Tuesday Markets	22-04-19	MT
Top Midday Gainers	22-04-19	MT
Sector Update: Health Care	22-04-19	MT
Checkmate Pharmaceuticals Shares Take Flight on Regeneron Deal	22-04-19	DJ
Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday	22-04-19	MT
Wall Street in Holding Pattern Pre-Bell as 10-Year Yield Tops 2.9%	22-04-19	MT
Sector Update: Health Care	22-04-19	MT
Top Premarket Gainers	22-04-19	MT
Regeneron to Buy Checkmate Pharmaceuticals for About $250 Million	22-04-19	DJ
Regeneron Pharmaceuticals Agrees to Buy Checkmate Pharmaceuticals in $250 Million All-Cash Deal	22-04-19	MT
Regeneron Pharmaceuticals, Inc. entered into a definitive agreement to acquire Checkmate Pharmaceuticals, Inc. from Decheng Capital China Life Sciences USD Fund III, L.P., a fund managed by Decheng Capital LLC, Arthur Krieg and others for approximately $250 million.	22-04-18	CI
Checkmate Pharmaceuticals Presents Clinical Trial Biomarker Data with Vidutolimod at the 2022 American Association for Cancer Research Annual Meeting	22-04-08	CI
BTIG Adjusts Checkmate Pharmaceuticals' Price Target to $9 from $29, Keeps Buy Rating	22-03-30	MT

Chart Checkmate Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Checkmate Pharmaceuticals, Inc. is a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer. The Company's product candidate, vidutolimod (CMP-001), is an advanced generation Toll-like receptor 9 (TLR9) agonist, delivered as a biologic virus-like particle (VLP) utilizing a CpG-A oligodeoxynucleotide as a key component, designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The Company is conducting a Phase II trial of vidutolimod in combination with nivolumab (OPDIVO), in anti-PD-1 refractory melanoma. The Company is also conducting a randomized Phase II/III trial of vidutolimod in combination with nivolumab in first-line melanoma. The Company's VLP technology is designed to encapsulate and protect the CpG-A oligonucleotide from degradation in the tumor.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-1.51%	105B
REGENERON PHARMACEUTICALS, INC.	+3.22%	97.5B
ARGENX SE	+1.86%	22.19B
BIONTECH SE	-16.53%	21.33B
GENMAB A/S	-8.49%	18.68B
WUXI APPTEC CO., LTD.	-42.33%	16.6B
BEIGENE, LTD.	-20.09%	14.52B
NEUROCRINE BIOSCIENCES, INC.	+5.47%	14.09B
SAREPTA THERAPEUTICS, INC.	+28.85%	10.99B

Bio Therapeutic Drugs